CLINICAL_TRIALS
trial_result
· 2015-03-17
Clinical Trial Update: Comparative Oral Bioavailability Study of MT-1303 [Phase 1]
Summary
Phase 1 study update evaluating the comparative oral bioavailability of MT-1303 in Relapsing-remitting Multiple Sclerosis has been completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tanabe Pharma Corporation | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 1 | Status: COMPLETED